In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why Value-Based Health Care Is Here To Stay

Necessity Is The Mother Of Invention

Executive Summary

COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.

You may also be interested in...



Technology’s place in value-based healthcare: HETTExpo 2012

Smart use of healthcare technology improves care delivery, saves time, increases productivity and can improve staff morale. At some point in the usage cycle, savings will start to be made, although when this happens – and whether it should be the prime reason for the adoption of IT-based healthcare delivery solutions – is open to debate. What is clear is that a modern approach is vital if state-provided healthcare, as we know it, is to remain sustainable in the long term. The private and public sectors both have key roles to play, says Ashley Yeo, at the second annual HETTExpo

Malaysia, Vietnam And Philippines Report Regulatory Compliance Progress And Pain Points

The latest Asian Regulatory Discussions heard about Malaysia’s five-year device certificate renewal concerns, Vietnam industry’s suggestion for device fast-task approval routes, and the Philippines industry’s transition needs as the country’s new AMDD-based regulatory system gets up and running. Device news from Singapore and Thailand was also reported at the September 2021 discussion teleconference, organized by the ARQon consultancy and the Asia Regulatory Professional Association.

MRA Or Not, Swiss Medtech Industry Urges Maximum Convergence With EU MDR

Swiss domestic medtech manufacturers reluctantly accept Switzerland’s new status as a third country to the EU, but the Swiss industry is anxious that new national regulations do not impose higher hurdles than the EU MDR. At present, there is a risk of that happening.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel